Jiangsu Nhwa Pharmaceutical002262.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Jiangsu Nhwa Pharmaceutical (002262.SZ) trades at a P/E of 19.80x, P/B of 2.59x, P/S of 3.37x, and a dividend yield of 1.87%.
Longitudinal percentile comparison: P/E sits at the 30th percentile over the trailing 10Y window (vs. 26th percentile over 3Y); P/B sits at the 5th percentile over the trailing 10Y window (vs. 11th percentile over 3Y); P/S sits at the 20th percentile over the trailing 10Y window (vs. 9th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 22nd percentile within its industry and the 24th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.87%, ranking at the 94th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 24.8 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Jiangsu Nhwa Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 002262 · SZSE: 002262 · 002262
Want the full picture on whether Jiangsu Nhwa Pharmaceutical (002262.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 19.80 | ||||||
| P/B (MRQ) | 2.59 | ||||||
| P/S (TTM) | 3.37 | ||||||
| Dividend Yield | 1.87% | ||||||
| Buyback + Div Yield | 1.87% |